Jonathan Sabbagh /Journey Clinical - Empowered psychedelic therapists can change lives

THE NEW HEALTH CLUB

Let’s celebrate. This is episode 100!

My guest is Jonathan Sabbagh, Co-Founder of Journey Clinical and I talk about normalising Ketamine therapy for all, plus why PTSD can fire up your career - until you realize it is harmful to you. Since a few years I am following Jonathan and his wife and Co-Founder Myriam Barthe’s great work around the idea to

build a strong, decentralized network and offerings for KAP (Ketamine Assisted Psychotherapy) to empower as much therapists as possible to execute the therapy.

They did an incredible and successful job to make Ketamine therapy available and build a strong system in collaboration with therapists and doctors.

In this episode is talk to Jonathan about:

-how PTSD can give you a skyrocketing career, until you realiize your “energy” is trauma in disguise

-how we both were very good in PTSD friendly jobs (banking & media) and left them because we realised our own PTSD

-how Journey Clinical helps therapists to support their patients with ketamine therapy, (eventually psilocybin) if they are interested in trying and

why normal “therapy” needs a strong transformation

What Journey Clinical does

Journey Clinical is on a mission to transform the growing mental health crisis by accelerating the mainstream adoption of legal, evidence-based Psychedelic-Assisted Psychotherapy as the standard of care for mental health, starting with Ketamine-Assisted Psychotherapy. They have built a leading platform for Psychedelic-Assisted Psychotherapy in the US. They also recently announce a research collaboration agreement with Compass Pathways to inform the development of a scalable delivery and training model for COMP360 psilocybin treatment. Which means, together with Compass, they work on a future delivery model for psilocybin therapy.

INFO

@journeyclinical

@Jonathansabbagh

www.https://www.journeyclinical.com/

.

---

Hosted on Acast. See acast.com/privacy for more information.